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Monoclonal Antibody-Mediated Tumor
Regression by Induction of Apoptosis
BERNHARD C. TRAUTH, CHRISTIANE KiAS, ANKE M. J. PETERS,
SIEGFRIED MATZKU, PETER MOLLER, WERNER FALK,
KLAUS-MICHAEL DEBATIN, PETER H. KRAMMER*
To characterize cell surface molecules involved in control of growth of malignant
lymphocytes, monoclonal antibodies were raised against the human B lymphoblast cell
line SKW6.4. One monoclonal antibody, anti-APO-1, reacted with a 52-kilodalton
antigen (APO-1) on a set of activated human lymphocytes, on malignant human
lymphocyte lines, and on some patient-derived leukemic cells. Nanogram quantities of
anti-APO-l completely blocked proliferation of cells bearing APO-1 in vitro in a
manner characteristic of a process called programmed cell death or apoptosis. Cell
death was preceded by changes in cell morphology and fragmentation of DNA. This
process was distinct from antibody- and complement-dependent cell lysis and was
mediated by the antibody alone. A single intravenous injection ofanti-APO-1 into nul
nu mice carrying a xenotransplant of a human B cell tumor induced regression of this
tumor within a few days. Histological thin sections of the regressing tumor showed
that anti-APO-1 was able to induce apoptosis in vivo. Thus, induction of apoptosis as
a consequence ofa signal mediated through cell surface molecules like APO-1 may be a
useful therapeutic approach in treatment of malignancy.
CEELL SURFACE MOLECULES ARE CRU-
cial in lymphocyte growth control.
Such molecules may function as re-
ceptors for growth-stimulating cytokines or
be associated with receptors and transmit
signals essential for growth regulation. Re-
ceptor blockade or removal of the stimulat-
ing cytokines can lead to decreased lympho-
cyte growth. Withdrawal of interleukins
slow human lymphocyte growth and finally
leads to a characteristic form of cell death
called "programmed cell death" or apoptosis
(1). Apoptosis is the most common form of
eukaryotic cell death and occurs in embryo-
genesis, metamorphosis, tissue atrophy, and
tumor regression (2). It is also induced by
cytotoxic T lymphocytes and natural killer
and killer cells; by cytokines like tumor
necrosis factor (TNF) and lymphotoxin
(LT); and by glucocorticoids (1, 2). The
most characteristic signs of apoptosis are
segmentation of the nucleus, condensation
of the cytoplasm, membrane blebbing, and
DNA fragmentation into multimers of
about 180 base pairs (called a "DNA lad-
der") (1, 2). To analyze mechanisms of
lymphocyte growth control and to interfere
with the replication oflymphoid tumor cells
we raised monoclonal antibodies (MAbs)
against cell surface molecules involved in
these processes.
We found one MAb (anti-APO-1) that
blocks growth and induces apoptosis of
SKW6.4 cells (3). Anti-APO-1 (IgG3, K,
KD = 1.9 x 10-10) bound to approximately
4 x 104 sites on the surface ofSKW6.4 cells
(4). It specifically immunoprecipitated an
endogenously synthesized protein antigen
(APO-1) from SKW6.4 cells which, under
reducing conditions, was observed on SDS-
Fig. 1. Molecular weight of
the cell surface antigen 97 -
APO-1: immunoprecip-
itation ofbiosynthetically la- 68-
beled APO-1 from the sur-
face of SKW6.4 cells with f
either isotype-matched con- 43- _
trol MAb (left lane) or anti-
APO-1 (right lane). The
numbers on the left margin
indicate the positions of the 25.7
size markers. Cells (3 x 106)
were labeled with 60 ,uCi of
75Se-labeled methionine 18.4
(Amersham, Braunschweig,
FRG) in 6 ml of methionine-free culture medium
(Biochrom, Berlin) for 48 hours. After washing,
the cells were incubated in either control MAb or
anti-APO-1 (1 ,ug/ml) at 4°C for 45 min. The
cells were washed and resuspended in lysis buffer
(tris-buffered saline,pH 7.3, 1% Nonidet P-40, 1
mM phenylmethylsulfonyl fluoride, 0.1% apro-
tinin) at room temperature for 30 min. The
lysates were centrifuged and supernatants were
incubated with protein A-Sepharose beads (Phar-
macia, Uppsala, Sweden) at 4°C for hour. The
immune complexes were washed four times with
buffer (tris-buffered saline, pH 7.3, 0.25% Noni-
det P-40) and resuspended in SDS-PAGE sample
buffer containing 5% SDS and 5% 2-mercapto-
ethanol. The samples were heated to 95°C, centri-
fuged, and counts per minute of the supernatants
were determined in a -y-counter. A total of 15,000
cpm were loaded in each lane and analyzed by a
10% SDS-PAGE (18). The gel was dried and
subjected to autoradiography.
polyacrylamide gel electrophoresis (SDS-
PAGE) as a main band of 52 kD (Fig. 1).
Apart from actin (43 kD), which was non-
specifically precipitated with IgG3, anti-
APO-1 specifically immunoprecipitated a
minor band of 25 kD. This 25-kD protein
might either represent a degradation prod-
uct or be noncovalently associated with the
52-kD protein.
There are two major modes of death in
nucleated eukaryotic cells. Necrosis as a
result, for example, of complement attack is
characterized by swelling of the cells and
rupture of the plasma membrane caused by
an increase in permeability. Cells that under-
go apoptosis, however, show a different
biochemical and morphological pattern (2).
This pattern corresponds to the one induced
by anti-APO-1: condensation of the cyto-
plasm, membrane blebbing (Fig. 2a), and
endonuclease-induced DNA fragmentation
(5) into multimers of approximately 180 bp
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(Fig. 2b). Affinity-purified anti-APO-1 in-
duced growth retardation and cell death
(Fig. 2c), which was not observed with
either an isotype-matched, control MAb
(FII20) [anti-MHC (major histocompatabi-
lity complex) class I antigens] or the non-
binding MAb FI123. Abrogation of
[3H]thymidine incorporation along with in-
creased trypan blue uptake into dead cells
were observed, and growth of 104 SKW6.4
cells in 200-,ul cultures was blocked by more
than 95% by an anti-APO-1 concentration
ofonly 10 ng/ml (Fig. 2c). The specificity of
cell death induced by anti-APO-1 becomes
evident from the fact that the following
additional control MAbs were inactive for
induction of apoptosis: 18 nonbinding and
9 binding MAbs of the IgG3 isotype (tested
by immunofluorescence on SKW6.4 cells)
and a panel ofMAbs directed against known
antigens on the cell surface of SKW6.4 cells
including CD 19, CD20, CD22, MHC class
II, IgM (immunoglobulin M), and the
SKW6.4 idiotype (6).
Cell death induced by anti-APO-1 was
complement-independent and occurred un-
der serum-free culture conditions or in cul-
ture medium plus serum inactivated at 56°C
for 30 min. It differed from death mediated
by complement-dependent lysis by: (i) mor-
phology and formation of a DNA ladder
(Fig. 2, a and b), (ii) exogenous Ca2+
independence (7), and (iii) delayed trypan
blue uptake and delayed 5'Cr release from
radiolabeled target cells (8). These experi-
ments indicate that cell death induced by
anti-APO- 1 is fumndamentally different from
antibody- and complement-dependent cell
lysis.
To assess the specificity of anti-APO-1, a
restricted panel of tumor cell lines was
screened for expression of APO-1 and sus-
ceptibility to growth inhibition and apopto-
sis. APO- 1 was expressed on various human
B M 0 20 40 60 90 120
pK
Fig. 2. Induction of growth inhibition and apoptosis by anti-
APO-1. (A) The T cell line CCRF-CEM.S2 (19) was cultured in
the presence of purified MAb (1 ,ug/ml) in a microtiter plate for
2 hours before photography (left panel control MAb 13B1;
right panel anti-APO-1). (B) CCRF-CEM.S2 cells (106 per
milliliter) were incubated with MAb (1 p.g/mi) in culture
medium at 37°C. At various times, aliquots of 106 cells were 100- C
removed and DNA was prepared. M, marker; I, control MAb
I3B1 for 2 hours; lanes 3 to 7, anti-APO-1 for the times .^ 0 0
indicated. (C) SKW6.4 cells were either incubated with the E
isotype-matched control MAb FII20 (0), FII23 (nonbinding '
MAb) (0), or anti-APO-1 (0) in microcultures for 24 hours °
before labeling with [3H]thymidine for a further 4 hours. The 10i
data represent the mean of duplicate cultures with a variation of a) 1
less than 5%. The cells were cultured in RPMI 1640 medium X 1
(Gibco, Grand Island, New York), supplemented with 2 mM L- a 1
glutamine, streptomycin (100 ,ug/ml), penicillin (100 U/ml), 20 \
mM Hepes bufferpH 7.3, and 10% heat-inactivated fetal bovine , 1
serum (Conco Lab-Division, Wiesbaden, FRG). For microcul- M
tures, 1 x 104 cells per well were cultured in duplicates in flat- . \
bottom 96-well microtiter plates (Tecnomara, Fermwald, FRG) ' 1
(200 ,ul final volume per well). After 24 hours, the cells were -.
labeled with 0.5 ,uCi of [3H]thymidine (Amersham, Braun- 0o11
schweig, FRG) for 4 hours. Before harvesting, the microcul- 1 01 102 103 104
tures were examined bv microscopic inspection. DNA fragmen-
tation 1 x 106 cells were washed with cold phosphate-buffered MAb (ng/ml)
saline and disrupted with NTE buffer, pH 8 (100mM NaC1, 10mM tris, 1 mM EDTA) containing 1%
SDS and proteinase K (0.2 mg/mi). After incubation for 24 hours at 37°C, samples were extracted twice
with phenol plus chloroform (1: 1, v/v) and precipitated by ethanol. The DNA was dissolved in 38 ,ul of
NTE buffer and digested with ribonuclease (1 mg/mi) for 30 min at 37C. To each sample 10 RI1 of
loading buffer containing 15% Ficoll 400 (Pharmacia, Uppsala, Sweden), 0.5% SDS, 50 mM EDTA,
0.05% bromophenol blue, 0.05% xylene cyanol in TBE buffer (2 mM EDTA, 89 mM boric acid, 89
mM tris, pH 8.4) were added. The mixture was loaded onto a 1% agarose gel and stained after
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Fig. 3. Anti-APO-1-induced regression of the
EBV-negative Burkitt-like lymphoma BJAB in
nu/nu mice. BJAB cells (4 x 107) were injected
subcutaneously into the left flank of nu/nu mice.
After 5 weeks (day 0) the mice were injected with
500 ,ug of MAb into the tail vein. Control MAb
FII20 (]); FII23 (0); I3B1 (A); and anti-APO-
1 (0). Fourteen days later the size of the tumors
was measured at the base of the tumor; the
tumors from individual mice are represented by
dots.
lymphoid B and T cell lines and was not
found on a gibbon or mouse T cell line or a
human monocytic cell line (Table 1). Anti-
APO-1 blocked proliferation ofthe APO-1-
positive cell lines listed in Table 1 via induc-
tion of apoptosis, and formation of a DNA
ladder was observed in each case (9). Expres-
sion ofAPO- 1 was not restricted to cell lines
in vitro but could be found on leukemic cells
freshly isolated from patients (Table 1).
Since APO- 1 was not found on all leukemic
cells it may be possible that anti-APO-l
defines a subpopulation of leukemias.
We also screened human B and T cells for
expression of APO- 1. We did not detect
APO-1 on resting B cells. However, APO-1
was expressed on activated B cells (Table 1)
and IgM secretion was reduced approxi-
mately fourfold by 3 days of treatment with
anti-APO-1 (10). Peripheral resting T cells
did not express APO- 1. Activated T cells,
however, expressed APO-1 and anti-APO-
1-induced apoptosis and growth inhibition
of these cells (Table 1). Thus, our data
suggest that APO- 1 is a species-specific anti-
gen expressed on activated or malignant
lymphocytes.
The striking effect of anti-APO- 1 in vitro
prompted us to test its effect on tumor
growth in vivo. Although the Epstein-Barr
virus (EBV)-negative, Burkitt-like lympho-
ma BJAB was the least sensitive to anti-
APO-1 of the B cell panel in Table 1 and
expressed only approximately 1.5 x 104
APO-1 epitopes per cell (4), we selected
BJAB for our in vivo experiments. The
reason for this choice was that only BJAB
grew to large tumor masses in unirradiated
































Fig. 4. Localization of anti- A
APO-1 in xenografts of BJAB 1 2 3
in nu/nu mice and induction of
apoptosis ofthe tumor. (A) Up- -
per row: uptake of '251-labeled
MAb anti-APO-1 (50 p.g, 50 - -
,uCi per mouse) in the tumor at
12 hours (1), 48 hours (2), and
96 hours (3) after intravenous
injection of the MAb. Lower
row: uptake of I5-labeled
MAb anti-APO-1 (500 ,ug, as
used for therapy; 50 ,uCi per
mouse) (4) and FII20 (control
MAb, binding to BJAB; 50 ,tgr, 4 5 6
50 ,uCi per mouse) (5) and 125-
labeled FII23 (control MAb, nonbinding to BJAB; 50 ,ug, 50 p.Ci per
mouse) (6) in 48 hours, respectively. (B) Ten days after intravenous
injection of 500 ,ug of MAb per mouse the remaining tumor tissue was
removed and fixed with formalin. Paraffin sections of the tumor were stained
with haematoxylin/eosin. Left panel, tumor after treatmnent with control
MAb FI120; right panel, tumor after treatment with anti-APO-1. Arrows
BJAB cells the nu/nu mice carried tumors
with a diameter of approximately 1.0 to 2.5
cm (Fig. 3). These mice were injected intra-
venously with purified anti-APO-l (500 p.g
per mouse) or the same quantities of various
isotype-matched control antibodies (FII20,
anti-MHC class I antigens, recognizing
5.8 x 105 sites per cell; or one of the two
nonbinding MAbs F1123 and 13B1). As a
control we also injected anti-APO-1 (500
,ug per mouse) into three nu/nu mice
carrying the APO-1-negative B cell tumor
OCILY1 with tumor diameters of 1.5, 1.8,
and 3.4 cm, respectively (11) (see also Table
1). Two days after anti-APO-1 injection, a
whitish discoloration of the BJAB tumors
was observed that was followed by rapid
tumor regression. Macroscopic tumor re-
gression was seen in 10 of 11 treated mice
within less than 14 days. The control anti-
bodies had no effect (Fig. 3). In addition, no
tumor regression was observed in the mice
carrying OCI.LY1, as expected.
To demonstrate proper localization and
enrichment of the injected antibodies, la-
beled MAbs were visualized by autoradiog-
raphy of sections of the BJAB tumor tissue
(Fig. 4a). These autoradiographs showed a
pronounced binding of anti-APO-1 in the
periphery but only sparse accumulation in
the center ofthe tumor. The binding control
MAb FII20 showed a qualitatively similar
binding pattern. There was no localization
of the nonbinding control MAb FI123
above background. Furthermore, paired la-
bel experiments (12) with labeled anti-
APO-1 and FII23 revealed that the specific
enrichment of anti-APO-1 over FI123 in
the tumor was four- and sixfold after 48 and
96 hours, respectively.
The main purpose ofour experiments was
to assess whether anti-APO- 1 can also act in
vivo. Therefore, the tumor-bearing mice
only received one intravenous injection of
anti-APO- 1 at a dose in the range used in
21 JULY I989
indicate host vessels. Final magnification, x 92. MAbs were radioiodinated
according to the IODO-Gen method (4). Labeled MAbs were injected into
the tail vein and animals were killed by ether anesthesia at the predetermined
time points. The tumors were excised and embedded in methylcellulose and
20-,um cryotome sections were prepared. Lyophilized sections were placed
on a Kodak X-omat AR film for autoradiography.
Table 1. Reactivity of anti-APO-1 with different cells.
Cells Relative Effects of MAbs on
Cells* positive fluorescence [3H]thymidine uptake
for intensity (103 cpm)t
APO-1 (anti-APO-1/
Type Designation (%)t control) Control Anti-APO-1
Malignant cell lines
Hu B cells SKW6.4 98 11.1 30.0 0.02
CESS 95 12.0 23.0 0.1
BJAB 80 2.1 70.0 7.0
OCI.LY1 0 1 14.5 15.8
Hu T cells Jurkat 83 2.3 20.3 8.1
Molt 91 2.4 35.7 0.6
CCRF-CEM 64 1.9 16.2 0.5
Hu myeloid cells U937 5 0.97 62.2 60.5
Gibbon T cells MLA 144 0 0.96 34.3 35.0
Mouse T cells EL4 0 1 44.8 45.3
Leukemic cells from patients§
PreT-ALL B.M. 54 4.4
T-ALL D.A. 53 3.2
Common ALL W.N. 72 5.0
Normal human lymphocytes
T cellsll Resting 3 1.36
Activated 89 7.4 22.4 0.23
B cells¶ Resting 0 0.9
Activated 91 1.1
*Hu, human; ALL, acute lymphocytic leukemia. tAliquots of 106 cells were incubated at 4°C in 100 ,ul of
medium with control MAb (RF23 or I3B1) or anti-APO- 1 for 30 min. Then the cells were washed and stained with
fluorescein isothiocyanate-coupled goat anti-mouse Ig F(ab')2(70 iLg/ml) and analyzed by a cytofluorograph (Ortho
Diagnostic Systems, Westwood, Massachusetts). tCells (104 per well) were cultured in the presence ofMAb (500
ng/ml) for 24 hours and labeled with [3H]thymidine for 2 hours before harvest; the data represent the mean of
duplicate cultures with a variation of less than 5%. §Bone marrow cells isolated from the patients were
mOrphologicay >95% blasts and showed the foHowing phenotype: pre T-ALL, cytoplasmic CD3+, CD5+, CD7+,
CD34, Tdt+, CD2-, surface CD3-, CD4-, and CD8-; T-ALL CD2', cytoplasmic CD3', CD5', CD7' and
Tdt+, surface CD3-, CD4-, CD8-, and CD34-; common-ALL CD10+, CD19+, CD22+, CD24+, CD20-. The
effect of anti-APO-1 on these leukemic cells was not tested, because they died under normal culture conditions.
IIPeripheral blood mononuclear cells (PBMC) from healthy volunteers were isolated by Ficoll Paque (Pharmacia Inc.,
Uppsala, Sweden) density centrifugation. Adherent cells were removed by adherence to plastic culture vessels
overnight. T cells were isolated from PBMC by rosetting with 2 amino-ethylisothyouronium-bromide (AET)-treated
she red blood cells as described (20). Freshly prepared resting T cells (2 x 10' per milliliter; 96% OKT11+, 1%
Tac) were activated with phytohemagglutinin-M (50 kg/mn) and PMA (10 ng/nil) (Sigma Chemical Co., Munich,
FRG). Two, 7, and 12 days later the T cells were fed with 20 to 30 U/mi of recombinant human interleukin-2 (20 to
30 U/mi). T cells (5 x 105 per milliliter) activated for 12 days (90% OKT11+; 60% Tac+) were cultured in the
presence of FI123 or anti-APO-1 (1 pLg/ml) in triplicates for 24 hours and then labeled with [3H]thymidine for a
further 17 hours (see legend to Fig. 2). ¶Resting B cells (35.8% CD19') were isolated by two rounds of rosetting
as above, followed b: separation via a Sephadex G-10 column as described (21). For activated B cells, PBMC were
adjusted to 2 x 10 cells per milliliter and cultured in the presence of pokeweed mnitogen at 10 j±g/ml (Serva,
Heidelberg, FRG) for 6 days. Dead cells and T cells were then eliminated by rosetting wit-h AET-treated sheep red
blood cells and subsequent centrifugation over Ficoll Paque. The interphase cells were used as activated B cells (84%
sIgM+).
MAb therapies. In other therapy schedules, tumor was observed in three of the ten mice
however, MAbs are injected repeatedly (13). in which tumor regression had been ob-
































the margin of the original tumor approxi-
mately 3 months after the initial macroscop-
ic tumor regression. One of these tumors
was removed and found to express APO-1
by immunofluorescence and to be sensitive
to anti-APO-l in vitro at a MAb concentra-
tion similar to the original in vitro BJAB
tumor cell line (Table 1).
To determine the histology of the regress-
ing BJAB tumors we prepared thin sections
of tumors from MAb-treated nu/nu mice.
Ten days after intravenous injection of
F1120, BJAB appeared as a solid tumor
composed of densely packed large blasts
with numerous mitoses, some tumor giant
cells, and rare apoptotic figures (Fig. 4b, left
panel). The tumor was penetrated by host
vessels. In contrast, almost all remaining
BJAB cells of mice treated with anti-APO-1
(Fig. 4b, right panel) showed severe cyto-
pathic changes including nudear pycnosis
and cellular edema most pronounced in
perivascular microareas. These morphologi-
cal changes are characteristic of apoptosis.
Taken together, these data strongly sug-
gest that apoptosis is induced by anti-APO-
1 and is the mechanism of death and regres-
sion of BJAB tumor cells in vivo. The fact
that FII20, which strongly binds to the cell
surface of BJAB tumor cells, did not cause
regression of BJAB also precludes the possi-
bility that killer cells or complement that
might have bound to anti-APO-1 may have
been involved in the growth inhibition and
tumor regression.
We showed that anti-APO-1 specifically
blocked growth and triggered programmed
cell death (apoptosis) of a set of activated
normal lymphocytes and cells from malig-
nant lymphocyte lines after binding to the
cell surface protein antigen APO- 1. Recent-
ly, it has been shown that anti-CD3 induces
apoptosis of immature thymocytes in vitro
(14). Therefore, it has been suggested that
CD3-triggered apoptosis might be responsi-
ble for negative selection of T cells in the
thymus. Since APO-1 is expressed on ma-
ture activated lymphocytes, additional ex-
periments will be needed to determine
whether the antigen might play a similar
role in the downregulation of the immune
response and be involved in selection and
elimination of lymphocytes. It has previous-
ly been shown that LT, TNF, and killer cells
with their effector molecules induce apopto-
tic cell death (15). As anti-APO-1 also
induces apoptosis a number of possibilities
might be considered for the physiological
role ofthe APO-1 antigen. APO-1 might be
a receptor for cytotoxic molecules or for
autocrine growth factors. Alternatively, it
could be a molecule essential for vertical or
lateral growth signal transduction. Thus,
anti-APO-1 might trigger receptors for lytic
molecules or block receptors for growth
signals.
Apoptosis is found in all tissues and also
in cells from lower organisms (16). It is
conceivable, therefore, that several distinct
cell surface antigens with a different tissue
distribution are involved in the induction of
apoptosis. Elucidation of the structure of
APO-1, its possible connection to the cyto-
skeleton and the molecular events following
anti-APO-1 binding might resolve some of
these issues.
Our data might also have clinical rele-
vance. APO- 1 was found on some lymphoid
tumor cells freshly isolated from patients.
Thus, anti-APO-1 might be usefufl as a
diagnostic tool to define subsets of normal
and malignant lymphocytes. In addition,
induction of apoptosis may have implica-
tions for anti-tumor therapy. Antibodies
have frequently been used as heteroconju-
gates with toxins or drugs to destroy tumor
cells (17). Our data, however, show that
MAb alone can be lethal to target cells.
Anti-APO-1 and related MAbs might,
therefore, be considered for ex vivo or in
vivo therapy, under conditions where reac-
tivity with vital normal cells can be excluded
or tolerated. Finally, the molecular investi-
gation of cell death induced by anti-APO-1
might lead to a general understanding of
apoptosis. In this case, the use of modified
or normal physiological ligands to the cell
surface antigen initiating apoptosis or of
chemicals interfering with the apoptotic sig-
nal might be envisaged.
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The Reservoir for HIV-1 in Human Peripheral Blood
Is a T Cell That Maintains Expression of CD4
STEVEN M. SCHNITrMAN,* MILTIADES C. PSALLIDOPOULOS,
H. CLIFFORD LANE, Louis THOMPSON, MICHAEL BASELER,
FERDINAND MASSARI, CECIL H. Fox, NoRMAN P. SALZMAN,
ANTHONY S. FAUCI
Human immunodeficiency virus type 1 (HIV-1) selectively infects cells expressing the
CD4 molecule, resulting in substantial quantitative and qualitative defects in CD4+ T
lymphocyte function in patients with acquired immunodeficiency syndrome (AIDS).
However, only a very small number of cells in the peripheral blood ofHIV-1-infected
individuals are expressing virus at any given time. Previous studies have demonstrated
that in vitro infection ofCD4+ T cells with HIV-1 results in downregulation ofCD4
expression such that CD4 protein is no longer detectable on the surface ofthe infected
cells. In the present study, highly purified subpopulations of peripheral blood
mononuclear cells (PBMCs) from AIDS patients were obtained and purified by
fluorescence-automated cell sorting. They were examined with the methodologies of
virus isolation by limiting dilution analysis, in situ hybridization, immunofluorescence,
and gene amplification. Within PBMCs, HIV-1 was expressed in vivo predominantly
in the T cell subpopulation which, in contrast to the in vitro observations, continued to
express CD4. The precursor frequency of these HIV-l1-expressing cells was about
1/1000 CD4+ T cells. The CD4+ T cell population contained HIV-1 DNA in all HIV-
1-infected individuals studied and the frequency in AIDS patients was at least 1/100
cells. This high level of infection may be the primary cause for the progressive decline
in number and finction of CD4+ T cells in patients with AIDS.
THHE HUMAN IMMUNODEFICIENCY
virus type 1 (HIV-1), the etiologic
agent of the acquired immunodefi-
ciency syndrome (AIDS), selectively infects
cells expressing the CD4 molecule, includ-
ing T lymphocytes and cells of the mono-
cyte/macrophage lineage (1). In vitro infec-
tion of cells with HIV-1 results in a de-
creased expression of the CD4 molecule on
the surface of the infected cells (2).
Patients with AIDS have severe depres-
sion of the normal cell-mediated immune
mechanisms that is partially attributed to the
considerable depletion of CD4 lymphocytes
(3). Despite this, examination of cells from
lymph nodes and peripheral blood from
patients with AIDS and AIDS-related com-
plex (ARC) has revealed a very low frequen-
cy of viral RNA synthesis, generally occur-
ring in 1/100,000 to 1/10,000 of total
mononuclear cells (4). However, it is possi-
ble that a larger proportion of cells may be
latently infected (containing proviral DNA
but not expressing viral mRNA or protein).
Until the development of gene amplification
[polymerase chain reaction (PCR)] method-
ology (5, 6), HIV-1-infected cells not ex-
pressing virus were not readily detectable by
available techniques.
In the present study, blood was obtained
from HIV-1 culture-positive patients with
AIDS either directly in heparinized syringes
or via apheresis and subjected to Ficoll-
Hypaque separation (7). First, peripheral
blood mononuclear cells (PBMCs) from pa-
tients were stained with fluorescein isothio-
cyanate (FITC)-conjugated antibody to
CD3 and sorted by a fluorescence-activated
cell sorter (FACS) into CD3+ and CD3-
populations. Sorted cells were cocultivated
with an excess of normal phytohemaggluti-
nin (PHA)-stimulated blast cells and we
determined the time to peak viral expres-
sion, a highly consistent and reproducible
parameter of viral expression. A predom-
inance of HIV-1 expression in the >98%
enriched CD3+ population, as determined
by the time to peak syncytia formation (Fig.
1A) and reverse transcriptase (RT) activity
(Fig. 1B), was seen. Similar results were
obtained in seven additional AIDS patients.
Delayed expression of HIV-1 in cells that
were initially 99% CD3- cells (Fig. 1B) was
due to outgrowth of the few contaminating
CD3+ cells. Phenotypic analysis of nonco-
cultivated enriched CD3- cells grown wuder
the same conditions revealed that 35 to 65%
ofthe cells were CD3+ by day 10 in culture.
In the second series of experiments,
PBMCs from AIDS patients were double-
stained with FITC-conjugated anti-CD3
and anti-CD4 and sorted by FACS into
CD3+/CD4+ and CD3+/CD4- popula-
tions. These sorted cells were cocultivated
with an excess of normal PHA-stimulated
blast cells and showed a predominance of
HIV- 1 expression in the highly enriched (98
to 99%) CD4+ T cell population as deter-
mined by the time to peak syncytia forma-
tion (Fig. IC) and RT activity (Fig. ID).
Similar results were obtained in seven addi-
tional AIDS patients. The phenotypic analy-
sis of freshly sorted CD3+/CD4+ cells re-
vealed a greater than 98 to 99% CD4+
purity in most experiments when stained
with the monoclonal antibody to Leu 3a.
Again, the delayed expression of HIV-1 in
cells that were initially 99% CD4- (Fig.
ID) was most likely due to outgrowth of a
few contaminating CD4+ T cells. Phenotyp-
ic analysis of non-cocultured enriched
CD4- T cells grown under the same condi-
tions revealed that 30 to 55% of the cells
were CD4+ by day 10 in culture.
In situ hybridization for HIV-1 viral
RNA was then performed at time zero on
the highly enriched CD3+/CD4+- and
CD3+/CD4--sorted PBMCs. There was a
predominance of viral expression in the
CD4+ T cell population at a frequency of
about 1/1000 cells in four AIDS patients (X
± SEM per 1000 cells was 0.95 ± 0.21)
(Fig. 2A). This is in comparison to a level of
viral expression in the CD4- T cell popula-
tion of <1/100,000 cells (Fig. 2B), which is
equivalent to background signal in controls.
The frequency of in situ-positive CD4+ T
cells remained unchanged in three of the
patients reexamined at 6 to 12 months after
the initial studies.
Indirect immunofluorescence studies for
HIV-1 viral antigens was also performed at
time zero on highly enriched CD3+/CD4+-
and CD3+/CD4--sorted PBMCs. These
demonstrate a predominance of viral expres-
sion in the CD4+ T cell population at a
frequency of about 1/1000 cells in four
AIDS patients (X ± SEM per 1000 cells
was 1.10 ± 0.35 (Fig. 2C). This is in com-
parison to a level of viral expression in the
CD4- T cell population of < 1/10,000 cells
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